Immatics (NASDAQ:IMTX) Lowered to “Sell” Rating by Wall Street Zen

Immatics (NASDAQ:IMTX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

IMTX has been the topic of several other reports. Guggenheim raised their price target on shares of Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Leerink Partners reissued an “outperform” rating and issued a $17.00 price objective on shares of Immatics in a research report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Mizuho set a $25.00 target price on shares of Immatics in a research note on Thursday, February 19th. Finally, Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Immatics in a report on Monday, November 24th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immatics presently has a consensus rating of “Moderate Buy” and an average target price of $19.20.

Immatics Stock Up 2.1%

NASDAQ IMTX opened at $10.34 on Friday. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $12.41. The business has a fifty day moving average of $9.91 and a 200-day moving average of $9.05. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -10.14 and a beta of 1.36.

Hedge Funds Weigh In On Immatics

A number of large investors have recently bought and sold shares of IMTX. T. Rowe Price Investment Management Inc. grew its stake in shares of Immatics by 10.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock valued at $225,322,000 after buying an additional 2,075,987 shares during the period. Virtus Investment Advisers LLC raised its position in shares of Immatics by 43.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company’s stock worth $278,000 after buying an additional 7,965 shares during the period. SummitTX Capital L.P. boosted its holdings in Immatics by 117.7% in the fourth quarter. SummitTX Capital L.P. now owns 96,784 shares of the company’s stock valued at $1,016,000 after acquiring an additional 52,318 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of Immatics in the 4th quarter valued at about $575,000. Finally, Sphera Funds Management LTD. lifted its stake in shares of Immatics by 47.7% in the 4th quarter. Sphera Funds Management LTD. now owns 861,105 shares of the company’s stock valued at $9,042,000 after purchasing an additional 278,000 shares in the last quarter. Hedge funds and other institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.